Lauren Silvernail

Track

Insider profile

Currently holds positions in Evolus Inc, Ista Pharmaceuticals LLC and Nicox SA

Performance

Overall performance
3.8
Performance over holding periods
3.8
30 days 90 days 120 days
Average return 9% 8.2% 15.1%
Success rate 93% 68% 82%
Transactions
5 20% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer, Executive Vice President - Corporate Development Evolus Inc May 29, 2018 -
Chief Financial Officer, Vice President - Corporate Development Ista Pharmaceuticals LLC March 1, 2003 -
Non-Executive Independent Director Nicox SA May 16, 2017 -
Chief Financial Officer, Chief Business Officer Revance Therapeutics Inc Dec. 14, 2015 - May 27, 2018
Chief Financial Officer, Executive Vice President of Corporate Development Revance Therapeutics Inc None -
Lauren Silvernail's trades of Harrow, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
US Harrow, Inc. (HROW)
Transaction date
Purchase
Price
421.04
Quantity 4,653 +1.8%
Value US$393,990
US Evolus Inc (EOLS)
Transaction date
Sale
Price
496.76
Quantity 5,104 -24.7%
Value US$2,224,357
US Evolus Inc (EOLS)
Transaction date
Sale
Price
189.66
Quantity 12,328 -37.9%
Value US$1,754,309
US Evolus Inc (EOLS)
Transaction date
Planned sale
Price
9.73
Quantity 10,192 -4.6%
Value US$99,121
US Evolus Inc (EOLS)
Transaction date
Planned sale
Price
7.46
Quantity 2,699 -2.9%
Value US$20,135
US Evolus Inc (EOLS)
Transaction date
Sale
Price
13.53
Quantity 2,612 -8.7%
Value US$35,352
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-19 2026-05-18
US Harrow, Inc. (HROW)
B Purchase
4,653 +1.8%
421.04
US$393,990 		4,653 +1.8% 421.04 US$393,990
2022-05-18 2022-05-18
US Evolus Inc (EOLS)
S Sale
5,104 -24.7%
496.76
US$2,224,357 		5,104 -24.7% 496.76 US$2,224,357
2022-05-18 2022-05-17
US Evolus Inc (EOLS)
S Sale
12,328 -37.9%
189.66
US$1,754,309 		12,328 -37.9% 189.66 US$1,754,309
2022-03-10 2022-03-08
US Evolus Inc (EOLS)
PlS Planned sale
10,192 -4.6%
9.73
US$99,121 		10,192 -4.6% 9.73 US$99,121
2021-01-26 2021-01-25
US Evolus Inc (EOLS)
PlS Planned sale
2,699 -2.9%
7.46
US$20,135 		2,699 -2.9% 7.46 US$20,135
2019-05-31 2019-05-31
US Evolus Inc (EOLS)
S Sale
2,612 -8.7%
13.53
US$35,352 		2,612 -8.7% 13.53 US$35,352
2017-05-24 2017-05-22
S Sale
1,793 -4.7%
20.20
US$36,212 		1,793 -4.7% 20.20 US$36,212